Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) insider Joan Nickerson sold 2,777 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $4.15, for a total value of $11,524.55. Following the completion of the sale, the insider now owns 17,420 shares of the company's stock, valued at $72,293. This represents a 13.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.
Verve Therapeutics Stock Performance
VERV opened at $3.85 on Friday. The firm has a market cap of $341.86 million, a price-to-earnings ratio of -1.57 and a beta of 1.77. The firm's 50-day simple moving average is $6.70 and its 200-day simple moving average is $6.04. Verve Therapeutics, Inc. has a twelve month low of $3.68 and a twelve month high of $9.31.
Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.14. The firm had revenue of $13.08 million for the quarter, compared to analysts' expectations of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. As a group, sell-side analysts anticipate that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.
Analysts Set New Price Targets
VERV has been the subject of several research reports. William Blair reaffirmed an "outperform" rating on shares of Verve Therapeutics in a research report on Friday, February 21st. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Verve Therapeutics in a report on Tuesday, March 25th. Guggenheim reissued a "buy" rating on shares of Verve Therapeutics in a research note on Tuesday, March 25th. Finally, Royal Bank of Canada cut their price target on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research note on Tuesday, March 4th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $20.67.
View Our Latest Analysis on VERV
Institutional Investors Weigh In On Verve Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of VERV. BVF Inc. IL boosted its stake in Verve Therapeutics by 962.2% in the fourth quarter. BVF Inc. IL now owns 6,904,050 shares of the company's stock worth $38,939,000 after purchasing an additional 6,254,050 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Verve Therapeutics in the fourth quarter valued at about $7,863,000. Schonfeld Strategic Advisors LLC lifted its position in Verve Therapeutics by 57.4% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company's stock worth $21,372,000 after buying an additional 1,382,176 shares in the last quarter. State Street Corp grew its holdings in Verve Therapeutics by 27.0% during the 3rd quarter. State Street Corp now owns 4,253,217 shares of the company's stock worth $20,586,000 after acquiring an additional 903,809 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its holdings in Verve Therapeutics by 72.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,559,393 shares of the company's stock worth $7,547,000 after acquiring an additional 653,578 shares during the last quarter. 97.11% of the stock is owned by institutional investors and hedge funds.
About Verve Therapeutics
(
Get Free Report)
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
